{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:17:42Z","timestamp":1784992662494,"version":"3.55.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/16078454.2023.2198098","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T13:38:15Z","timestamp":1681133895000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3159-9629","authenticated-orcid":false,"given":"Yufeng","family":"Du","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-2602","authenticated-orcid":false,"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_3_2_3_1","unstructured":"Acute Myeloid Leukemia (AML) SEER 22 2015\u20132019 All Races Both Sexes."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16359"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205075"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.09.001"},{"key":"e_1_3_2_7_1","unstructured":"Surveillance Research Program National Cancer Institute. All cancer sites combined: recent trends in SEER age-adjusted incidence rates 2000-2019 by sex delay-adjusted SEER incidence rate all races all ages. Accessed June 22 2022."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.09.001"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00376-1"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00965-1"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010120"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.01.040"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25567"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106803"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab170"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100791"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_3_2_20_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03 (2010) Us Department of Health and Human Services. National Institutes of Health National Cancer Institute. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5\u2009(\u20097.pdf."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005538"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25859"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071734"},{"issue":"1","key":"e_1_3_2_30_1","first-page":"14","article-title":"Efficacy, and patient-reported outcomes of venetoclax in combination With azacitidine for the treatment of patients With higher-risk myelodysplastic syndrome: A phase 1b study","volume":"19","author":"Jacqueline S","year":"2020","unstructured":"Jacqueline S, Safety GM. Efficacy, and patient-reported outcomes of venetoclax in combination With azacitidine for the treatment of patients With higher-risk myelodysplastic syndrome: A phase 1b study. Clin Adv Hematol Oncol. 2020;19(1):14\u201316.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007265"},{"issue":"21","key":"e_1_3_2_33_1","first-page":"6557","article-title":"Real world results of venetoclax combined with hypomethylating agents in relapsed\/refractory AML","volume":"25","author":"Ucar MA","year":"2021","unstructured":"Ucar MA, Ozet G, Koyuncu MB, et al. Real world results of venetoclax combined with hypomethylating agents in relapsed\/refractory AML. Eur Rev Med Pharmacol Sci. 2021;25(21):6557\u20136565.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124994"},{"issue":"3","key":"e_1_3_2_35_1","first-page":"290","article-title":"Hypomethylating agents\u2009+\u2009venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country","volume":"11","author":"Mirgh S","year":"2021","unstructured":"Mirgh S, Sharma A, Shaikh M, et al. Hypomethylating agents\u2009+\u2009venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11(3):290\u2013302.","journal-title":"Am J Blood Res"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab018"},{"key":"e_1_3_2_37_1","first-page":"181","article-title":"Venetoclax (Ven) with azacitidine (Aza) for untreated elderly acute myeloid leukemia (AML) patients (Pts) unfit for induction chemotherapy: single center clinical experience and mechanistic insights from correlative studies","volume":"130","author":"Pollyea DA","year":"2017","unstructured":"Pollyea DA, Stevens BM, Winters A, et al. Venetoclax (Ven) with azacitidine (Aza) for untreated elderly acute myeloid leukemia (AML) patients (Pts) unfit for induction chemotherapy: single center clinical experience and mechanistic insights from correlative studies. Blood. 2017;130:181.","journal-title":"Blood"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000243"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124437"},{"issue":"4","key":"e_1_3_2_40_1","first-page":"213","article-title":"Efficacy of the Combination of Venetoclax and Azacitidine in Elderly of Frail Relapsed\/Refractory Patients with Acute Myeloid Leukemia, First Multi-Institutional Real World Experience from Turkey","volume":"30","author":"Aktimur SH","year":"2020","unstructured":"Aktimur SH, Gunes AK, Akidan O, et al. Efficacy of the Combination of Venetoclax and Azacitidine in Elderly of Frail Relapsed\/Refractory Patients with Acute Myeloid Leukemia, First Multi-Institutional Real World Experience from Turkey. UHOD - Uluslar Hematol-Onkol Derg. 2020;30(4):213\u2013221.","journal-title":"UHOD - Uluslar Hematol-Onkol Derg"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106317"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Labrador J Saiz-Rodr\u00edguez M de Miguel D et al. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers (Basel). 2022;14(7):1734.","DOI":"10.3390\/cancers14071734"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1843752"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.01.024"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778225"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.65"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00870-3"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3102"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33403"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2023.2198098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T12:10:55Z","timestamp":1702296655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2023.2198098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/16078454.2023.2198098"],"URL":"https:\/\/doi.org\/10.1080\/16078454.2023.2198098","relation":{},"ISSN":["1607-8454"],"issn-type":[{"value":"1607-8454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2198098"}}